NCT02985827View on ClinicalTrials.gov

Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Dry Eye

Interventions

DRUG

Rohto (r) Hydra

Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose

DRUG

Systane (r) Ultra

Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose

All Listed Sponsors

lead

ORA, Inc.

INDUSTRY

NCT02985827 - Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) | Biotech Hunter | Biotech Hunter